Advertisement

Schilddrüse

  • J. Feldkamp
  • W. A. Scherbaum

Zusammenfassung

Die Schilddrüse entwickelt sich aus einer Ausstülpung des Entoderms in der Mitte der Mundbucht in der 3. Woche nach der Konzeption. Nach einer zweilappigen Auf teilung wandert die Schilddrüse vom Ausgangspunkt, dem Foramen coecum, kaudalwärts. Der Ductus thyreoglossus, die Verbindung zwischen Foramen coecum und endgültiger Lage der Schilddrüse etwa in Höhe des 2.-4. Trachealringes, obliteriert postpartal. Nicht selten bildet der kaudale Anteil des Ductus thyreoglossus den Lobus pyramidalis. Beide Schilddrüsenlappen bleiben durch den prä tracheal gelegenen Isthmus verbunden. Die Schilddrüse setzt sich aus zahllosen Follikeln zusammen, die aus einzelnen, aneinander gereihten Zellen bestehen, die einen mit Kolloid gefüllten Hohlraum umgeben. Im Kolloid werden Schilddrüsenhormone im Thyreoglobulinmolekül gespeichert und synthetisiert.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

Literatur zu Abschn. 4.1

  1. Beato M. (1989) Gene regulation by steroid hormones. Cell 56: 335PubMedCrossRefGoogle Scholar
  2. Chopra I.J., Solomon D.H., Chopra U. et al. (1978) Pathways of metabolism of thyroid hormones. Recent Prog Horm Res 34: 521PubMedGoogle Scholar
  3. Cody V. (1980) Thyroid hormone interactions: molecular con formation, protein binding and hormone action. Endocr Rev 1: 140PubMedCrossRefGoogle Scholar
  4. Dai G., Levy O., Carrasco N. (1996) Cloning and characterisation of the thyroid iodide symporter. Nature 379: 458–460PubMedCrossRefGoogle Scholar
  5. Dunn A.D., Dunn J.T. (1982) Thyroglobulin degradation by thyroidal proteases: action of thiol endopeptidases in vitro. Endocrinology 111: 290PubMedCrossRefGoogle Scholar
  6. Evans E.M. (1988) The steroid and thyroid hormone reeeptor superfamily. Science 240: 889PubMedCrossRefGoogle Scholar
  7. Hinkle P.M., Perrone M.H., Schonbrunn A. (1981) Mechanism of thyroid hormone inhibition of thyrotropin-releasing hormone action. Endocrinology 108: 199PubMedCrossRefGoogle Scholar
  8. Köhrle J., Brabant G., Hesch H.D. (1987) Metabolism of thyroid hormones. Hormone Res 26: 58PubMedCrossRefGoogle Scholar
  9. Lama L., Taurog A. (1977) The importance of thyroglobulin structure in thyroid peroxidase-catalysed conversion of diiodotyrosine to thyroxine. Endocrinology 100: 1129CrossRefGoogle Scholar
  10. Laurberg P. (1984) Mechanisms governing the relative proportions of thyroxine and 3,5,3’. triiodothyronine in thyroid secretion. Metabolism 33: 379PubMedCrossRefGoogle Scholar
  11. Leonard J.L., Meilen S.A., Larsen P.R. (1983) Thyroxine 5’-deiodinase activity in brown adipose tissue. Endocrinology 112: 1153PubMedCrossRefGoogle Scholar
  12. Magner J.A. (1990) Thyroid-stimulating hormone: biosynthesis, cell biology and bioactivity. Endocr Rev 11: 354PubMedCrossRefGoogle Scholar
  13. Nunez J., Pommier J. (1982) Formation of thyroid hormones. Vitam Horm 39: 175PubMedCrossRefGoogle Scholar
  14. Roti E., Gnudi A., Bravermann L.E. (1983) The placental transport, synthesis, and metabolism of hormones and drugs which affect thyroid function. Endocr Rev 4: 131PubMedCrossRefGoogle Scholar
  15. Sakurai A., Nakai A., DeGroot L.J. (1990) Structural analysis of human thyroid hormone rcccplor beta gene. Mol Cell Endocrinol 71: 83PubMedCrossRefGoogle Scholar
  16. Sap J., Munoz A., Damm K. et al. (1986) Ther c-erb-A protein is a high affinity receptor for thyroid hormone. Nature 324: 635PubMedCrossRefGoogle Scholar
  17. Snyder S.M., Cavalieri R.R., Goldfine I.D., Ingbar S.H., Jorgensen S.E. (1976) Binding of thyroid hormones and their analogues to thyroxine-binding globulin in human serum. J Biol Chem 251: 6489PubMedGoogle Scholar
  18. Uchimura H., Chiu S.C., Kuzuya N., Ikeda H., Ito K., Nagataki S. (1980) Effect of iodine enrichment in vitro on the ade nylate cyclase-adenosine 3’, 5’ monophophate system in thyroid glands from normal subjects and patients with Graves’ disease. J Clin Endocrinol Metab 50: 1066PubMedCrossRefGoogle Scholar

Literatur zu Abschn. 4.2-4.7

  1. Ahlbom B.D., Yaqoob M., Larsson A., Ilicki A., Anneren G., Wadelius C. (1997) Genetic and !inkage analysis of familial congenital hypothyroidism: exclusion of !inkage to the TSH receptor gene. Hum Genet 99: 186–190PubMedCrossRefGoogle Scholar
  2. Amino N., Mori H., Iwatani Y. et al. (1982) High prevalence of transient postparturn thyrotoxicosis and hypothyroidism. N Engl J Med, 306: 849–852PubMedCrossRefGoogle Scholar
  3. Badenhoop K., Schwarz G., Walfish P.G. et al. (1990) Susceptibility to thyroid autoimmune disease: moleeular analysis of HLA-D region genes identifies new markers for goitrous Hashimoto’s thyroiditis. J Clin Endocrinol Metab 71: 1131–1137PubMedCrossRefGoogle Scholar
  4. Baker J.R. (1992) Immunologie aspects of endocrine disease. JAMA 25: 2899–2903CrossRefGoogle Scholar
  5. Bartalena L., Brogioni S., Grasso L., Bogazzi F., Burelli A., Martino E. (1996) Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge: Results of a prospective study. J Clin Endocrinol Metab 81: 2930–2933PubMedCrossRefGoogle Scholar
  6. Basgoz N., Swartz M.N. (1996) Infections of the thyroid gland. In: Braverman L.E., Utiger R.D. (Hrsg) Werner and Ingbar’s the thyroid. 7th edn, Lippincott & Raven, Philadelphia, pp 1049–1056Google Scholar
  7. Berger S.A., Zonzein J., Villamena P., Mittman N. (1983) Infectious diseases of the thyroid gland. Rev Infect Dis 5: 108–122PubMedCrossRefGoogle Scholar
  8. Biebermann H., Schoneberg T., Krude H., Schultz G., Gudermann T., Grüters A. (1997) Mutations of the human thyrotropin receptor gene causing thyroid hypoplasia and persistent congenital hypothyroidism. J Clin Endocrinol Metab 82: 3471–3480PubMedCrossRefGoogle Scholar
  9. Brander A. (1992) Ultrasound appearances in de Quervain’s subacute thyroiditis with longterm follow-up. J Intern Med 232: 321–325PubMedCrossRefGoogle Scholar
  10. Dayan C.M., Daniels G.H. (1996) Chronie auto immune thyroiditis. N Engl J Med 335: 99–107PubMedCrossRefGoogle Scholar
  11. De Bruin T.W.A., Rieckhoff F.P.M., DeBoer J.J. (1990) An outbreak of thyrotoxicosis due to atypical subacute thyroiditis. J Clin Endocrinol Metab 70: 396–402PubMedCrossRefGoogle Scholar
  12. De Catte L., De Wolf D., Smitz J., Bougatef A., De-Schepper J., Foulon W. (1994) Fetal hypothyroidism as a complication of amiodarone treatment for persistent fetal supraventricular tachycardia. Prenat Diagn 14: 762–765PubMedCrossRefGoogle Scholar
  13. DeGroot L.I., Quintans J. (1990) The causes of auto immune thyroid disease. Endocr Rev 10: 537–562CrossRefGoogle Scholar
  14. Delange F. (1997) Neonatal screening for congenital hypothyroidism: results and perspectives. Horm Res 48: 51–61PubMedCrossRefGoogle Scholar
  15. Gärtner R. (1992) Post-partum-Thyreoiditis-Definition. Häufigkeit und klinische Bedeutung. Internist 33: 100–102PubMedGoogle Scholar
  16. Giordano C., Stassi G., Demaria R. et al.(1997) Potential involvement of fas and its ligand in the pathogenesis of Hashimoto’s thyroiditis. Science 275: 960–963PubMedGoogle Scholar
  17. Gladwin M.T., Duell P.B. (1996) Inappropriate thyroid gland ablation in patients with generalized resistance to thyroid hormone. A common sequela of a rare dis order. Arch Intern Med 156: 106–109PubMedCrossRefGoogle Scholar
  18. Glinoer D., Riahi M., Grün J.P. (1994) Risk of subclinical hypothyroidism in pregnant women with asymptomatic autoimmune thyroid dis orders. J Clin Endocrinol Metab 79: 197–204PubMedCrossRefGoogle Scholar
  19. Gutekunst R., Hafermann W., Mansky T., Scriba P.C. (1989) Ultrasonography related to clinical and laboratory findings in lymphocytic thyroiditis. Acta Endocrinol 121: 129–135PubMedGoogle Scholar
  20. Harjai K.J., Licata A.A. (1997) Effects of amiodarone on thyroid function. Ann Intern Med 126: 63–73PubMedCrossRefGoogle Scholar
  21. Hay I.D. (1985) Thyroiditis: a clinical update. Mayo Clin Proc 60: 836–843PubMedCrossRefGoogle Scholar
  22. Hehrmann-R. (1996) Myxödem-Koma-eine seltene Komplikation der Hypothyreose. Mögliche iatrogene Auslösefaktoren beachten. Fortsehr Med 114: 474–478Google Scholar
  23. Heller J., Musiolik J., Homrighausen A., Sauerbruch T., Spengler U. (1996) Vorkommen und Bedeutung von Autoantikörpern im Rahmen der Interferontherapie der chronischen Hepatitis C. Dtsch Med Wschr 121: 1179–1183PubMedCrossRefGoogle Scholar
  24. Heufelder A.E., Hay I.D. (1994) Evidence for autoimmune mechanisms in the evolution of invasive fibrous thyroiditis (Riedel’s struma). Clin Invest 72: 788–793CrossRefGoogle Scholar
  25. Heufelder, Armin E., Hofbauer, Lorenz C. (1998) Die Thyreoiditiden: Aktueller Stand der Pathogenese, Diagnostik und Therapie. Dt Ärztebl 95:A466–A476Google Scholar
  26. Jansson R., Bernander S., Karlsson A. et al. (1984) Autoimmune thyroid dysfunction in the postparturn period. J Clin Endocrinol Metab 58: 681–687PubMedCrossRefGoogle Scholar
  27. Jordan R.M. (1995) Pathophysiology, therapy, and factors affecting prognosis. Med Clin North Am 79: 185–194PubMedGoogle Scholar
  28. Kasagi K., Kousaka T., Higuchi K. et al. (1996) Clinical significance od measurements of antithyroid antibodies in the diagnosis ofHashimoto’s thyroiditis: comparison with histological findings. Thyroid 6: 445–450PubMedCrossRefGoogle Scholar
  29. Klein I., Levey G.S. (1982) Silent thyrotoxic thyroiditis. Ann Intern Med 96: 242–244PubMedCrossRefGoogle Scholar
  30. Kujat C., Dyck R., Brederhoff J., Pfannenstiel P. (1991) Diagnose und Therapie der subakuten Thyreoiditis de Quervain. Dtsch Med Wschr 116: 1439–1443PubMedCrossRefGoogle Scholar
  31. Kuten A., Lubochitski R., Fishman G., Dale J., Stein M.E. (1996) Postradiotherapy hypothyroidism: radiation dose response and chemotherapeutic radiosensitization at less than 40 Gy. J Surg Oncol 61: 281–283PubMedCrossRefGoogle Scholar
  32. Labib M., Gama R., Wright J., Marks V., Robins D. (1989) Dietary maladvice as a cause ofhypothyroidism and short stature. BMJ 298: 232–233PubMedCrossRefGoogle Scholar
  33. Lazarus J.H., Othman S. (1991) Thyroid disease in relation to pregnancy. Clin Endocrinol 34: 91–98CrossRefGoogle Scholar
  34. Lecuit M., Caumes E., Bricaire F., Gatineau M., Ménégaux F., Gentilini M. (1995) Acute suppurative Salmonella enteritidis thyroiditis in a patient with the human immunodeficiency virus. Clin Infect Dis 20: 196PubMedCrossRefGoogle Scholar
  35. Lio S., Pontocorvi A., Caruso M. et al. (1984) Transitory subclinical and permanent hypothyroidism in the course of subacute thyroiditis (de Quervain). Acta Endocrinol 106: 67–70PubMedGoogle Scholar
  36. Marazuela M., Garcia-Buey L., Gonzalez-Fernandez B. et al.(1996) Thyroid auto immune disorders in patients with chronie hepatitis C before and during interferona-therapy. Clin Endocrinol 44: 635–642CrossRefGoogle Scholar
  37. Nikolai T.F., Coombs G.J., McKenzie A.K. et al. (1982) Treatment of lymphocytie thyroiditis with spontaneously resolving hyperthyroidism (silent thyroiditis). Arch Int Med 142: 2281–2283CrossRefGoogle Scholar
  38. Othman S., Phillips D.I., Parkes A.B. et al. (1990) A long-term follow up of postparturn thyroiditis. Clin Endocrin 32: 559–564CrossRefGoogle Scholar
  39. Peter S.A. (1992) Painful subacute thyroiditis (De Quervain’s thyroiditis). J Nat Med Assoc 84: 877–879Google Scholar
  40. Ramchandani D., Schindler B.A. (1993) The lithium toxie patient in the medical hospital: diagnostie and management dilemmas. Int J Psychiatry Med 23: 55–62PubMedCrossRefGoogle Scholar
  41. Rapoport B. (1991) Pathophysiology of Hashimoto’s thyroiditis and hypothyroidism. Ann Rev Med 42: 91–96PubMedCrossRefGoogle Scholar
  42. Robillon J.F., Sadoul J.L., Guerin P. et al.(1994) Mycobacterium avium intracellulare suppurative thyroiditis in a patient with Hashimoto’s thyroiditis. J Endocrinol Invest 17: 133–134PubMedGoogle Scholar
  43. Roti E., Minelli R., Giuberti T. et al. (1996) Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with reeombinant inferferon-alpha. Am J Med 172: 482–487CrossRefGoogle Scholar
  44. Safran M., Paul T.L., Roti E. (1987) Environmental faetors affecting auto immune thyroid disease. Endocrinol Metab Clin North Am 16: 327–342PubMedGoogle Scholar
  45. Scherbaum W.A., Paschke R. (1995) Bedeutung der Schilddrüsenantikörper für Diagnostik und Verlaufsbeurteilung von Schilddrüsenerkrankungen. Internist 36: 303–309PubMedGoogle Scholar
  46. Scherbaum-W.A. (1987) On the clinical importance of thyroid microsomal and thyroglobulin antibody determination. Acta Endocrinol Suppl Copenh 281: 325–329PubMedGoogle Scholar
  47. Schwartzentruber D.J., White D.E., Zweig M.H., Weintraub B.D., Rosenberg S.A. (1991) Thyroid dysfunction associated with immunotherapy for patients with cancer. Cancer 68: 2384–2390PubMedCrossRefGoogle Scholar
  48. Shiegmasa C., Ueta Y., Mitani Y. et al. (1985) Chronic thyroiditis with painful tender thyroid enlargement and transient thyrotoxicosis. J Clin Endocrinol Metab 70: 385–390CrossRefGoogle Scholar
  49. Shigemasa C., Kouchi T., Taniguchi S., Mitani Y., Ueta Y., Yoshida A. (1991) Autoimmune thyroiditis with transient thyroxicosis: comparison between painful thyroiditis and painful thyroiditis. Horm Res 36: 9–15PubMedCrossRefGoogle Scholar
  50. Singer P.A. (1991) Thyroiditis: acute, subacute, and chronic. Med Clin North Am 75: 61–77PubMedGoogle Scholar
  51. Skuza K., Rapaport R., Fieldman R., Goldstein S. (1991) Recurrent acute suppurative thyroiditis. J Otolaryngol 20: 126–129PubMedGoogle Scholar
  52. Szabo S.M., Allen D.B. (1989) Thyroiditis. Differentiation of acute suppurative and subacute. Case report and review of the literature. Clin Pediatr 28: 171–174CrossRefGoogle Scholar
  53. Tachi J., Amino N., Tamaki H. et al. (1988) Long-term follow-up and HLA association in patients with post partum hypothyroidism. J Clin Endocrinol Metab 66: 480–484PubMedCrossRefGoogle Scholar
  54. Takami H., Kozakai M. (1994) Tuberculous thyroiditis: Report of a case with review of the literature. Endocr J 41: 743–747PubMedCrossRefGoogle Scholar
  55. Takasu N., Komiya I., Asawa T., Nagasawa Y., Yamada T. (1990) Test for recovery from hypothyroidism during thyroxine therapy in Hashimoto’s thyroiditis. Lancet 336: 1084–1086PubMedCrossRefGoogle Scholar
  56. Tomer Y., Barbesino G., Greenberg D., Davies T.F. (1997) The immunogenetics of autoimmune diabetes and autoimmune thyroid disease TEM 8: 63–70PubMedGoogle Scholar
  57. Tomer Y., Davies T.F. (1993) Infection, thyroid disease, and autoimmunity. Endocr Rev 14: 107–120PubMedGoogle Scholar
  58. Tunbridge W.M. (1979) The epidemiology of hypothyroidism. Clin Endocrinol Metab 8: 21–27PubMedCrossRefGoogle Scholar
  59. Tunbridge W.M., Brewis M., French J.M. et al. (1981) Natural history of autoimmune thyroiditis. Br Med J Clin Res Ed 24: 258–262, 282CrossRefGoogle Scholar
  60. Vanhole C., Aerssens P., Naulaers G., Casneuf A., Devlieger H., Van den Berghe G., de Zegher F. (1997) L-thyroxine treatment of preterm newborns: clinical and endocrine effects. Pediatr Res 42: 87–92PubMedCrossRefGoogle Scholar
  61. Volpe R. (1993) The management of subacute (De Quervain’s) thyroiditis. Thyroid 3: 253–255PubMedCrossRefGoogle Scholar
  62. Wilichowski E., Grüters A., Kruse K. et al. (1997) Hypoparathyroidism and deafness associated with pleioplasmic large scale re arrangements of the mitochondrial DNA: a clinical and molecular genetic study of four children with Kearns Sayre syndrome. Pediatr-Res 41: 193–200PubMedCrossRefGoogle Scholar

Literatur zu Abschn. 4.8

  1. Chatterjee V.K.K. (1994) Resistance to thyroid hormone-an uncommon cause of thyroxine excess and inappropriate TSH secretion. Acta med austriaca 21: 56–60PubMedGoogle Scholar
  2. De Nayer P. (1992) The thyroid hormone receptors: molecular basis of thyroid hormone resistance. Horm Res 38: 57–61PubMedCrossRefGoogle Scholar
  3. Dorey F.G., Strauch G., Gayno J.P. (1990) Thyrotoxicosis due to pituitary resistance to thyroid to thyroid hormones. Succsessful control with D-thyroxine. A study in three patients. Clin Endocrinol 32: 221CrossRefGoogle Scholar
  4. Dulgeroff A.J., Geffner M.E., Koyal S.N., Wong M., Hershmann J.M. (1992) Bromocriptin and Triac therapy for hyperthyroidism due to pituitary resistance to thyroid hormone. J Clin Endocrinol Metab 75: 1071PubMedCrossRefGoogle Scholar
  5. Feldkamp J., Seppel T., Horster F.A. (1995) Hyperthyroxinämie bei nichtsupprimiertem TSH. Differentialdiagnose und Therapie. Dtsch Med Wschr 120: 1323–1326PubMedCrossRefGoogle Scholar
  6. Franklyn J.A. (1993) Thyroid hormone resistance syndromesare generalized and selective pituitary resistance part of the same disorder? Clin Endocrinol 38: 235–236CrossRefGoogle Scholar
  7. McDermott M.T., Ridgway E.C. (1993) Thyroid hormone resistance syndromes. Am J Med 94: 424–432PubMedCrossRefGoogle Scholar
  8. Mixson A.J., Hauser P., Tennyson G., Renault J.C., Bodenner D.L., Weintraub B.D. (1993) Differential expression of mutant and normal beta T3 receptor alleles in kindreds with generalized resistance to thyroid hormone. 91: 2296–2300Google Scholar
  9. Nagaya T., Eberhardt N.L., Jameson J.L. (1993) Thyroid hormone resistance syndrome: correlation of dominant negative activity and location of mutations. J Clin Endocrinol Metab 77: 982–990PubMedCrossRefGoogle Scholar
  10. Ueda S., Takamatsu J., Fukata S. et al. (1996) Differences in response of thyrotropin to 3,5,3’-triiodothyronine and 3,5,3’-triiodothyroacetic acid in patients with resistance to thyroid hormone. Thyroid 6: 563–570PubMedCrossRefGoogle Scholar
  11. Usala, S.J., Bale A.E., Gesundheit N., Weinberger C. et al. (1988) Tight linkage between the syndrom of generalized thyroid hormone resistance and the human c-erb A ß gene. Mol Endocrinol 2: 1217PubMedCrossRefGoogle Scholar
  12. Weiß R.E., Refetoff S. (1992) Thyroid hormone resistance. Ann Rev Med 43: 363–375PubMedCrossRefGoogle Scholar
  13. Yen P.M., Sugawara A., Refetoff S., Chin W.W. (1992) New insights on the mechanism(s) of the dominant negative effect of mutant thyroid hormone receptor in generalized resistance to thyroid hormone. 90: 1825–1831Google Scholar

Literatur zu Abschn. 4.9

  1. Beck-Peccoz P., Persani L., Mantovani S., Cortelazzi D., Asteria C. (1996) Thyrotropin-secreting pituitary adenomas. Metabolism 45: 75–79PubMedCrossRefGoogle Scholar
  2. Boni G., Ferdeghini M., Bellina C.R. et al. (1995) [111In-DTPA-DPhe]-octreotide scintigraphy in functioning and nonfunctioning pituitary adenomas. Q J Nucl Med 39 (Suppl 1 ):90–93PubMedGoogle Scholar
  3. Chanson P., Orgiazzi I., Derome P.J. et al. (1984) Paradoxical response of thyrotropin to L-dopa and presence of dopaminergic receptors in a thyrotropin-secreting pituitary adenoma. J Clin Endocrinol Metab 59: 542–546PubMedCrossRefGoogle Scholar
  4. Feldkamp J., Seppel T., Horster F.A. (1995) Hyperthyroxinämie bei nichtsupprimiertem TSH. Differentialdiagnose und Therapie. Dtsch Med Wsehr 120: 1323–1326CrossRefGoogle Scholar
  5. Lee E.J., Kim K.R., Lim S.K., Lee H.C., Kim D.I., Kim S.H., Huh K.B. (1994) Reduction in size of a thyrotropin-seereting pituitary adenoma treated with octreotide acetate (somatostatin analog). Eur J Endocrinol 131: 109–112PubMedCrossRefGoogle Scholar
  6. Losa M., Giovanelli M., Persani L., Mortini P., Faglia G., Beck-Peccoz P. (1996) Criteria of eure and follow-up of central hyperthyroidism due to thyrotropin-secreting pituitary adenomas. J Clin Endocrinol Metab 81: 3084–3090PubMedCrossRefGoogle Scholar
  7. Losa M., Magnani P., Mortini P. et al. (1994) Mod-pathol. clinical and immunohistochemical studies on TSH-secreting pituitary adenoma: its multihormonality and expression of Pit-1. Dec 7: 893–839Google Scholar
  8. Malarkey W.B., Kovacs K., O’Dorisio T.M. (1989) Response of a GH-and TSH-secreting pituitary adenoma to a somatostatin analogue (SMS 201-995): evidenee that GH and TSH coexist in the same cell and secretory granules. Neuroendocrinology 49: 267–274PubMedCrossRefGoogle Scholar
  9. Mixson A.J., Friedman T.C., Katz D.A. et al. (1993) Thyrotropinseercting pituitary carcinoma. J Clin Endocrinol Metab. 76: 529–533PubMedCrossRefGoogle Scholar
  10. Takano K., Ajima-M., Teramoto A., Hata K., Yamashita N. (1995) Mechanisms of action of somatostatin on human TSH-secreting adenoma cells. Am J Physiol 268: E558–564PubMedGoogle Scholar
  11. Tschakert H., Hokamp H.G. (I989) Zur Frage der Bestrahlung TSH-sezernierender Hypophysenadenome. Strahlenther Onkol 165: 47–51Google Scholar

Literatur zu Abschn. 4.70-4.77

  1. Allanic H., Fauchet R., Orgiazzi J. et al. (1990) Antithyroid drugs and Graves’ disease. A prospective randomized evaluation of the efficacy of treatment duration. J Clin Endocrinol Metab 70: 675–679CrossRefGoogle Scholar
  2. Bahn R.S., Dutton C.M., Heufelder A.E., Sarkar G. (1994) A genomic point mutation in the extracellular domain of the TSH receptor in patients with Graves’ ophthalmopathy. J Clin Endocrinol Metab 78: 256–260PubMedCrossRefGoogle Scholar
  3. Barlow A.B.T., Wheatcroft N., Watson P., Weetman A.P. (1996) Association of HLA-DQA1 *0501 with Graves’ disease in English Caucasian men and women. Clin Endocrinol 44: 73–78CrossRefGoogle Scholar
  4. Bartalena L., Marocci C., Bogazzi F., Panicucci M., Lepri A., Pinchera A. (1989) Use of corticosteroids to prevent progression of Graves’ ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med 321: 1349–1352PubMedCrossRefGoogle Scholar
  5. DeGroot L.J., Quintans J. (1989) The causes of auto immune thyroid disease. Endocr Rev 10: 537–562PubMedCrossRefGoogle Scholar
  6. Edmonds C.J., Tellez M. (1994) Treatment of Graves’ disease by carbimazole: high dose with thyroxine compared to titration dose. Europ J Endocrinol 131: 120–124CrossRefGoogle Scholar
  7. Farrar J.J., Toft A.D. (1991) Iodine-131 treatment of hyperthyroidism: current issues. Clin Endocrinol 35: 207–212CrossRefGoogle Scholar
  8. Feldt-Rasmussen U., Schleusener H., Carayon P. (1994) Metaanalysis evaluation of the impact of thyrotropin receptor antibodies on long term remission of medical therapy for Graves’ disease. J Clin Endocrinol Metab 78: 98–103PubMedCrossRefGoogle Scholar
  9. Hashizume K., Ichikawa K., Sakurai A. et aL.(1991) Administration of thyroxine in treated Graves’ disease. Effects on the level of antibodies to thyroid-stimulating receptors and on the risk of recurrence of hyperthyroidism. N Engl J Med 324: 947–53PubMedCrossRefGoogle Scholar
  10. Hedley A.J., Young R.E., Jones S.J., Alexander W.D., Bewsher P.D. (1989): Antithyroid drugs in the treatment ofhyperthyroidism of Graves’ disease. Long-term follow-up of 434 patients. Clin Endocrinol 31: 209–218CrossRefGoogle Scholar
  11. Heuer M., Aust G., Ode-Hakim S., Scherbaum W.A. (1996) Different cytokine mRNA profiles in Graves’ disease, Hashimoto’s thyroiditis, and non auto immune thyroid disorders determined by quantitative reverse transcriptase polymerase chain reaction (RT-PCR). Thyroid 6: 97–106PubMedCrossRefGoogle Scholar
  12. Hoermann R., Schumm-Draeger P.M., Mann K. (1993): Inhibition of functional and immunological responses to thyroid-stimulating antibodies from patients with Graves’ disease by blockade of the thyrotropin receptor. Thyroid 3: 273–278PubMedCrossRefGoogle Scholar
  13. Hofbauer C., Hörmann R., Heufelder E. (1996) M. Basedow: Neuester Stand zur Pathogenese, Diagnostik und Therapie. Dt Ärztebl 93:A2690–2696Google Scholar
  14. Kahaly G., Stover C., Otto E., Beyer J., Schuler.M (1992) Glycosaminoglycans in thyroid-associated ophtalmopathy. Autoimmunity 13: 81–88PubMedCrossRefGoogle Scholar
  15. Kosugi S., Ban T., Akamizu T., Kohn L.D. (1992) Identification of separate determinants on the thyrotropin receptor reactive with Graves’ thyroid-stimulating antibodies and with thyroid-stimulating blocking antibodies in idiopathic myxedema: these determinants have no homologous sequence on gonadotropin receptors. Mol Endocrinol 6: 168–180PubMedCrossRefGoogle Scholar
  16. Luo G.L., Fan J.F., Seetharamaiah G.S. (1993) Immunization of mice with Yersinia enterocolitica leads to the induction of antithyrotropin receptor antibodies. J Immunol 151: 922–928PubMedGoogle Scholar
  17. McIver B., Rae P., Beckett G., Wilkinson E., Gold A., Toft A. (1996) Lack of effect of thyroxine in patients with Graves’ hyperthyroidism who are treated with an antithyroid drug. N Engl J Med 334: 220–224PubMedCrossRefGoogle Scholar
  18. Morgenthaler N.G., Tremble J., Huang G., Scherbaum W. A., McGregor A.M., Banga J.P. (1996) Binding of antithyrotropin receptor autoantibodies in Graves’ disease serum to nascent, in vitro translated thyrotropin receptor: ability to map epitopes recognized by antibodies. J Clin Endocrinol Metab 81: 700–706PubMedCrossRefGoogle Scholar
  19. Prummel M., Mourits M., Berghout A., Krenning E.P., van der Gaag R., Koorneef L., Wiersinga W.M. (1989) Prednisone and cyclosporine in the treatment of severe Graves’ ophtalmopathy. N Engl J Med 321: 1353–1358PubMedCrossRefGoogle Scholar
  20. Prummel M.F., Wiersinga W.M. (1993) Smoking and risk of Graves’ disease. J Am Med Assoc 269: 479–482CrossRefGoogle Scholar
  21. Prummel M.F., Wiersinga W.M., Mourits M.P., Koornneef L., Berghout A., van der Gaag R. (1990) Influence of abnormal thyroid function on the severity of accompanying Graves’ ophthalmopathy. Arch Int Med 150: 1098–1101CrossRefGoogle Scholar
  22. Reiners C. (1993) Radioiodtherapie. Indikation, Durchführung und Risiken. Dt Ärztebl:B2217–B2221Google Scholar
  23. Reinwein D., Benker G., Lazarus J.H., Alexander W.D., and the European Multicenter Study Group on antithyroid drug treatment (1993) A prospective randomized trial of antithyroid drug dose in Graves’ disease therapy. J Clin Endocrinol Metab 76: 1516–1521PubMedCrossRefGoogle Scholar
  24. Reinwein D., Röher H-D., Emrich D. (1993) Therapie der Hyperthyreose: Aktueller Stand. Dtsch Med Wochenschr 118: 1036–1043PubMedCrossRefGoogle Scholar
  25. Romaldini J.H., Bromberg N., Werner R.S. et al.(1983) Comparison of effects ofhigh and low dosage regimens of antithyroid drugs in the management of Graves’ hyperthyroidism. J Clin Endocrinol Metab 57: 563–570PubMedCrossRefGoogle Scholar
  26. Schleusener H., Peters H., Fischer C., Bogner U., Finke R., Kotulla P. (1992) Ist eine Verlaufsprognose nach thyreostatischer Behandlung bei Basedow-Hyperthyreose möglich? Akt Endokr Stoffw 13: 47–52Google Scholar
  27. Tallstedt L., Lundell G., Blomgren H., Bring J. (1994) Does early tratment of thyroxine reduce the development of Graves’ ophtalmopathy after radioiodine treatment? Eur J Endocrinol 130: 494–497PubMedCrossRefGoogle Scholar
  28. Tallstedt L., Lundell G., Torring O. et al.(1992) Occurrence of ophthalmopathy after treatment for Graves’ disease hyperthyroidism. N Engl J Med 326: 1733–1738PubMedCrossRefGoogle Scholar
  29. Tomer Y., Davies T.F. (1993) Infection, thyroid disease, and autoimmunity. Endocr Rev 14: 107–120PubMedGoogle Scholar
  30. Weetman A.P., McGregor A.M. (1994) Autoimmune thyroid disease: further developments in our und erst an ding. Endocr Rev 15: 778–830Google Scholar
  31. Winsa B., Adami H.O., Berstrom R. (1991) Stressfullife events and Graves’ disease. Lancet 338: 1475–1479PubMedCrossRefGoogle Scholar
  32. Yanagawa T., Mangklabruks A., DeGroot L.J. (1994) Strong association between HLA-DQA1 *0501 and Graves’ disease in a male Caucasian population. J Clin Endocrinol Metab 79: 227–229PubMedCrossRefGoogle Scholar

Literatur zu Abschn. 4.12

  1. Als C., Listewnik M., Ritter H.P., Rosler H. (1997) Szintigraph isches Verfahren zur Quantifizierung der morphologischen und funktionellen Veränderungen der thyreoidalen Autonomie vor und nach Radioiodtherapie. Schweiz Med Wochenschr 127: 102–106PubMedGoogle Scholar
  2. Azizi F. (1985) Environmental iodine intake affects the response to methimazole in patients with diffuse toxic goiter. J Clin Endocrinol Metab 61: 374–377PubMedCrossRefGoogle Scholar
  3. Becker W., Börner W., Gruber G. (1986) Szintigraphie und Sonographie bei der Diagnostik der Schilddrüsenautonomie. Deutsch Med Wochenschr 111: 1630–1635CrossRefGoogle Scholar
  4. Derwahl M., Hamacher C., Russo D. et al. (1996) Constitutive activation of the Gs alpha protein-adenylate cyclase pathway may not be sufficient to generate toxic thyroid adenomas. J Clin Endocrinol Metab 81: 1898–1904PubMedCrossRefGoogle Scholar
  5. Emrich D., Erlenmaier U., Pohl M. et al. (1993) Determination of the autonomously functioning volume of the thyroid. Eur J Nucl Med 20: 410–414PubMedCrossRefGoogle Scholar
  6. Führer D., Holzapfel H.P., Wonerow P., Scherbaum W. A., Paschke R. (1997) Somatic mutations in the thyrotropin receptor gene and not in the Gs alpha pro tein gene in 31 toxic thyroid nodules. J Clin Endocrinol Metab 82: 3885–3891PubMedCrossRefGoogle Scholar
  7. Hamburger J.I. (1980) Evolution of toxicity in solitary nontoxic autonomously functioning thyroid nodules. J Clin Endocrinol 50: 1089–1093CrossRefGoogle Scholar
  8. Holzapfel H.P., Führer D., Wonerow P., Weinland G. Scherbaum W. A., Paschke R. (1997) Identification of constitutively activating somatic thyrotropin receptor mutations in a subset of toxic multinodular goiters. J Clin Endocrinol Metab 82: 4229–4233PubMedCrossRefGoogle Scholar
  9. Kabadi U., Cech R. (1994) Therapeutic 1311 dose in hyperthyroidism: role of pretreatment with thionamide. Thyroidology 6: 87–92PubMedGoogle Scholar
  10. Klein B., Klein E., Horster F.A. (1989) Ergebnisse der fraktionierten Radioiodtherapie bei 696 Hyperthyreosen und 690 blanden Strumen. Nuklearmedizin 28: 129–36PubMedGoogle Scholar
  11. Kopp P., Kimura E.T., Aeschimann S., Oestreicher M., Tobler A., Fey M.F., Studer H. (1994) Polyclonal and monoclonal thyroid nodules coexist within human multinodular goiters. J Clin Endocrinol Metab 79: 134–139PubMedCrossRefGoogle Scholar
  12. Luster M., Jacob M., Thelen M.H., Michalowski U., Deutsch U., Reiners C. (1995) Reduktion des Schilddrüsenvolumens nach Radioiodtherapie wegen funktioneller Autonomie. Nuklearmedizin 34: 57–60PubMedGoogle Scholar
  13. Melliere D., Etienne G., Becquemin J.P. (1988) Operation for hyperthyroidism. Methods and rationale. Am J Surg 1988 155: 395–399PubMedCrossRefGoogle Scholar
  14. Paschke R. (1996) Constitutively activating TSH receptor mutations as the cause of toxic thyroid adenoma, multinodular toxic goiter and autosom al dominant non autoimmune hyperthyroidism. Exp Clin Endocrinol Diabetes 104, Suppl 4: 129–132PubMedCrossRefGoogle Scholar
  15. Peter H.J., Gerber H., Studer H., Peterson M.E., Becker D.V., Groscurth P. (1991) Autonomous growth and function of cultured thyroid follicles from cats with spontaneous hyperthyroidism. Thyroid 1: 331–338PubMedCrossRefGoogle Scholar
  16. Röher H.D., Goretzki P.E. (1987) Management of goiter and thyroid nodules in an area of endemic goiter. Surg-ClinNorth-Am 67: 233–249Google Scholar
  17. Sawin C.T., Geiler A., Wolf P.A. et al. (1994) Low thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 331: 1249–1252PubMedCrossRefGoogle Scholar
  18. Studer H., Derwahl M. (1995) Mechanisms of nonneoplastic endocrine hyperplasia-achanging concept: a review focused on the thyroid gland. Endocr. Rev 16: 411–426PubMedGoogle Scholar
  19. Utiger R.D. (1994) Subclinical hyperthyroidism-just a low thyrotropin concentration, or something more. N Engl J Med 331: 1302–1303PubMedCrossRefGoogle Scholar

Literatur zu Abschn. 4.13

  1. Boyages S.C. (1993) Iodine deficiency disorders. J Clin Endocrinol Metab 77: 587–591PubMedCrossRefGoogle Scholar
  2. Brunn J., Block U., Ruf G. (1981) Volumetrie des Schilddrüsenlappens mittels real time-Sonographie. Dtsch Med Wochenschr 41: 1338–1340CrossRefGoogle Scholar
  3. Delange F. (1994) The disorders induced by iodine deficiency. Thyroid 4: 107PubMedCrossRefGoogle Scholar
  4. Einenkel D., Bauch K.H., Benker G. (1992) Treatment of juvenile goitre with levothyxroxine, iodide or a combination of both: the value of ultrasound grey-scale analysis. Acta Endocrinol 127: 301PubMedGoogle Scholar
  5. Errick J.E., Ing K.W.A., Eggo M.C., Burrow G.N. (1986) Growth and differentiation in cultured human thyroid cells: effects of epidermal growth factor and thyrotropin. In vitro Cell Dev Biol 22: 28PubMedCrossRefGoogle Scholar
  6. Feldkamp J., Seppel T., Becker A., Klisch A., Schlaghecke R., Goretzki P.E., Röher H.O. (1997) Iodide or L-Thyroxine to prevent recurrent goiter in an iodine-deficient area: prospective sonographic study. World J Surg 21: 10–14PubMedCrossRefGoogle Scholar
  7. Feldkamp J., Seppel T., Mühlmeyer M., Becker A., Santen R., Schlaghecke R., Horster F.A. (1996) Therapie der endemischen Struma mit Iodid oder L-Thyroxin bei älteren Patienten. Dtsch Med Wochenschr 121: 1587–1591PubMedCrossRefGoogle Scholar
  8. Gärtner R. (1987) Strumatherapie mit Schilddrüsenhormon oder Iodid. Dtsch med Wochenschr 112: 987PubMedCrossRefGoogle Scholar
  9. Geerdsen J.P., Frolund L. (1984) Recurrence of nontoxic goitre with and without postoperative thyroxine medication. Clin Endocrinol 21: 529CrossRefGoogle Scholar
  10. Glinoer D., De-Nayer P., Delange F. et al. (1995) A randomized trial for the treatment of mild iodine deficiency during pregnancy: matern al and neonatal effects. J Clin Endocrinol Metab 80: 258PubMedCrossRefGoogle Scholar
  11. Goretzki P., Frilling A., Simon D., Rastegar M., Ohmann C. (1989) Growth regulation of human thyrocytes by thyrotropin, cyclic adenosine monophosphate, epidermal growth factor and insuline-like growth factor. In Growth regulation of thyroid gland and thyroid tumors. Karger, Basel, pp 56–80Google Scholar
  12. Grubeck-Loebenstein B., Buchan G., Sadeghi R. et al. (1989) Transforming growth factor beta regulates thyroid growth. Role in the pathogenesis of nontoxic goiter. J Clin Invest 83: 764PubMedCrossRefGoogle Scholar
  13. Gutekunst R., Magiera U., Teichert H-M. (1993) Iodmangel in der Bundesrepublik Deutschland. Med Klinik 88: 525Google Scholar
  14. Gutekunst R., Smolarek H., Hasenpusch U., Stubbe P., Friedrich H-J., Wood W.G., Scriba P.C. (1986) Goitre epidemiology: Thyroid volume, iodine excretion, thyroglobulin and thyrotropin in Germany and Sweden. Acta Endocrinol 112: 494PubMedGoogle Scholar
  15. Hampel R., Kühlberg T., Klein K. et al. (1995) Strumaprävalenz in Deutschland größer als bisher angenommen. Med Klinik 90: 324Google Scholar
  16. Hehrmann R. (1990) Medikamentöse Therapie der Iodmangelstruma bei Kindern, Jugendlichen, jungen Erwachsenen und Schwangeren. Sozialpädiatrie 12: 92Google Scholar
  17. Hintze G., Emrich D., Köbberling J. (1985) Therapy of endemic goitre. Controlled study on the effect of iodine and thyroxine. Horm metabol Res 17: 362CrossRefGoogle Scholar
  18. Hintze G., Windeiner S., Baumgart S., Stein H., Köbberling J. (1991) Thyroid volume and goitre prevalence in the elderly. Acta Endocrinol 124: 12PubMedGoogle Scholar
  19. Hotze A., Bockisch A., Briele B., Horst M., Ruhlmann J., Biersack H.J. (1989) Therapie der Iodmangelstruma mit Levothyroxin und einer Kombination aus Iodid und Levothyroxin. Nuc Comp 20: 166Google Scholar
  20. Kahaly G., Mihaljevic V., Beyer J., Krause U. (1989) Thyroxin vs Iod und Thyroxin. Schweiz Med Wochenschr 119: 59PubMedGoogle Scholar
  21. Köbberling J., Hintze G. (1988) Therapie der endemischen Struma. Internist 29: 550PubMedGoogle Scholar
  22. Koutras D.A., Karaiskos K.S., Piperingos G.D. et al. (1986) Treatment of endemic goitre with iodine and thyroid hormones, alone or in combination. Endocrinologia Experimentalis 20: 57PubMedGoogle Scholar
  23. Laurberg P. (1994) Editorial: Iodine intake-what are we aiming at? J Clin Endocrinol Metab 79: 17PubMedCrossRefGoogle Scholar
  24. Leisner B., Henrich B., Knorr D., Kantlehner R. (1985) Effect of iodide treatment on iodine concentration and volume of endemic non-toxic goitre in childhood. Acta Endocrinol 108: 44PubMedGoogle Scholar
  25. Liesenkötter K.P., Göpel W., Bogner U., Stach B., Grüters A. (1996) Earliest prevention of endemic goiter by iodine supplementation. Europ J Endocrinol 134: 443CrossRefGoogle Scholar
  26. Mandel S.J., Brent G.A., Larsen P.R. (1993) Levothyroxine therapy in patients with thyroid disease. Ann Intern Med 119: 492–502PubMedCrossRefGoogle Scholar
  27. Manz F., Fuchs A., Terwolbeck K., Wiese B., Lombeck I. (1993) Iodversorgungszustand gesunder Säuglinge in Deutschland. Klin Pädiatr 205: 424PubMedCrossRefGoogle Scholar
  28. Olbricht Th., Hoff H-G., Benker G., Wagner R., Reinwein D. (1985) Sonographische Volumetrie der Schilddrüse zur Verlaufskontrolle hei einer Thyroxin-und Iodidbehandlung der blanden Struma. Otsch Med Wochenschr 110: 863CrossRefGoogle Scholar
  29. Pfannenstiel P. (1988) Therapie der endemischen Struma mit Levothyroxin und Iodid. Dtsch Med Wochenschr 113: 326.PubMedCrossRefGoogle Scholar
  30. Pickardt C.R., Köbberling J. (1989) Therapie der endemischen Struma. Endokrinologie-Informationen 13: 150Google Scholar
  31. Saller B., Hoermann R., Ritter R. (1991) Course of thyroid iodine concentration during treatment of endemie goitre with iodine and a combination of iodine and levothyroxine. Acta Endocrinol 125: 662PubMedGoogle Scholar
  32. Sawin C.T., Geiler A., Wolf P.A. et al. (1994) Low serum thyreotropin concentrations as a risk factor for atrial fibrillation in older persons. New Engl J Med 331: 1249PubMedCrossRefGoogle Scholar
  33. Sehumm-Dräger P.M. (1993) Medikamentöse Strumatherapie. Iodid, Schilddrüsenhormone oder kombinierte Therapie. Innere Medizin 48: 592Google Scholar
  34. Seriba P.C., Beckers C., Bürgi A. et al. (1985) Goitre and iodine defieiency in Europe. Report of the Subcommitee for the Study of endemie Goitre and Iodine Defieieney of the European Thyroid Assoeiation. Lancet 1: 1289Google Scholar
  35. Stübner D., Gärtner R., Greil W. et al. (1987) Hypertrophy and hyperplasia du ring growth and involution in rats-separate bioeffects ofTSH and iodine. Acta Endocrinol 116: 537PubMedGoogle Scholar
  36. Studer H., Peter H.J., Gerber H. (1989) Natural heterogeneity of thyroid eells: the basis for understanding thyroid function and nodular goiter growth. Endocr Rev 10: 125PubMedCrossRefGoogle Scholar
  37. Uzzan B., Campos J., Cucherat M., Nony P., Boissei J.P., Perret G.Y. (1996) Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis. J Clin Endocrinol Metab 81: 4278–4289PubMedCrossRefGoogle Scholar
  38. Wawsehinek O., Eber O., Petek W., Wakonig P., Gürakar A. (1985) Bestimmung der Harniodausscheidung mittels einer modifizierten Cer-Arsenit-Methode. Berichte der ÖGKC 8: 14Google Scholar
  39. Wilders-Truschnig M.M., Warnkroß H., Leb G. et al. (1993) The effect of treatment with levothyroxine or iodine on thyroid size and thyroid growth stimulating immunoglobulins in endemie goitre patients. Clin Endocrinol 39: 281CrossRefGoogle Scholar
  40. Wilgerodt A., Stach B., Keller E., Ockert C. (1990) Welchen Einfluss hat eine verbesserte alimentäre Iodversorgung. Therapiewoche 40: 2085Google Scholar

Literatur zu Abschn. 4.74

  1. Aust G., Eichier W., Laue S. et al. (1997) CD97: a dedifferentiation marker in human thyroid carcinomas. Cancer Res 57: 1798–1806PubMedGoogle Scholar
  2. Biondi B., Fazio S., Carella C. et al. (1993) Cardiac effects oflong term thyrotropin-suppressive therapy with levothyroxine. J Clin Endocrinol Metab 77: 334–338PubMedCrossRefGoogle Scholar
  3. De Groot L.J., Kaplan E.L., McCormick M., Straus F.H. (1990) Natural history, treatment and course of papillary thyroid carcinoma. Clin Endocrinol Metab 71: 414–424CrossRefGoogle Scholar
  4. De Groot L.J., Kaplan E.L., Straus F.H., Shukla M.S. (1994) Does the method of management of papillary thyroid carcinoma make a difference in outcome? World J Surg 18: 123–130CrossRefGoogle Scholar
  5. Dralle H., Schwarzrock R., Lang W., Böcker W., Ziegler H., Schröder S., Geerlings H. (1985) Comparison of histology and immuno-histochemistry with thyroglobulin serum levels and radioiodine uptake in recurrences and metastases of differentiated thyroid carcinomas. Acta Endocrinol 108: 504–510PubMedGoogle Scholar
  6. Eising E.G., Farahati J., Bier D. Knust E.J., Reiners C. (1995) Somatostatinrezeptorszintigraphie bei medullären Schilddrüsenkarzinomen, GEP-Tumoren und Karzinoiden. Nucl Med 34: 1–7Google Scholar
  7. Farahati J., Reiners C., Stuschke M., Muller S.P., Stuben G., Sauerwein W., Sack H. (1996) Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4). Cancer 77: 172–180PubMedCrossRefGoogle Scholar
  8. Feldkamp J. (1998) Endokrine Therapie und Nachsorge beim Schilddrüsenkarzinom. Schweiz Rundsch Med 87: 389–393Google Scholar
  9. Girelli M.E., Busnardo B., Amerio R. et al. (1985) Serum thyroglobulin levels in patients with well-differentiated thyroid cancer during suppression therapy. Study on 429 patients. Europ J Nucl Med 10: 252–254Google Scholar
  10. Goretzki P.E., Frilling A., Ohmann C., Wins L., Grußendorf M., Röher H.D. (1989) Unterschiedliche Strategien in Diagnostik und Therapie des Schilddrüsenkarzinoms. Chirurg 60: 398–402PubMedGoogle Scholar
  11. Hay I.D., Bergstralh E.J., Goellner J.R., Ebersold J.R., Grant C.S. (1993) Predicting outcome in papillary thyroid earcinoma: development of a reliable prognostie scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114: 1050–1058PubMedGoogle Scholar
  12. Kerr D.J., Burt A.D., Boyle P. (1986) Prognostic factors in thyroid tumors. Br J Cancer 54: 475–482PubMedCrossRefGoogle Scholar
  13. Lips C.J.M., Landsvater R.M., Höppener W.M. et al. (1994) Clinical screening as compared with DNA analysis in families with multiple endoerine neoplasia Type 2a. N Engl J Med 331: 828–835PubMedCrossRefGoogle Scholar
  14. Mazzaferri E.L., Sissy M., Jhiang S.M. (1994) Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97: 418–429PubMedCrossRefGoogle Scholar
  15. Müller-Gaertner H.W., Brzac H.T., Rehpenning W. (1991) Prognostic indices for tumor relapse and tumor mortality in follicular thyroid carcinoma. Cancer 67: 1903–1922CrossRefGoogle Scholar
  16. Mulligan L.M., Kwok J.B.J., Healey C.S. et al. (1993) Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2a (MEN 2 A). Nature 363: 458–469PubMedCrossRefGoogle Scholar
  17. Panza N., de Rosa M., Lombardi G., Salvatore M. (1985) Usefulness of serum thyroglobulin at replacement withdrawal after thyroidectomy for differentiated thyroid cancer. J Nucl Med 26: 316–317PubMedGoogle Scholar
  18. Raue F., Frank-Raue K., Grauer A. (1994) Multiple endoerine neoplasia type 2, clinical features, and screening. Endocrin. Metab Clin North Am 23: 137–156Google Scholar
  19. Röher H.D., Simon D., Witte J., Goretzki P.E. (1994) Principals of limited or radical surgery for differentiated thyroid cancer. Thyroidology 5: 93–96Google Scholar
  20. Samaan N.A., Schultz P.N., Hickey R.C., Goepfert H., Haynie T.P., Johnston D.A., Ordonez N.G. (1992) The results of various modalities of treatment of weil differentiated thyroid carcinoma: a retrospective review of 1599 patients. J Clin Endocrinol Metab 75: 714–720PubMedCrossRefGoogle Scholar
  21. Sawin C.T., Geiler A., Wolf P.A. et al. (1994) Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med. 331: 1249–1252PubMedCrossRefGoogle Scholar
  22. Schelfhout L.J., Creutzberg C.L., Hamming J.F. et al. (1988) Multivariate analysis of survival in differentiated thyroid cancer: the prognostic significance of the age factor. Eur J Cancer Clin Oncol. 24: 331–337PubMedCrossRefGoogle Scholar
  23. Schlumberger M., Tubiana M., de Vathaire F. et al. (1986) Longterm results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab 63: 960–966PubMedCrossRefGoogle Scholar
  24. Sherman S.T., Tielens E.T., Sostre S., Wharam M.D. Jr., Ladenson P.W. (1994) Clinical utility of post-treatment radioiodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab 78: 629–634PubMedCrossRefGoogle Scholar
  25. Solbiati L., Volterrani L., Rizzatto G. et al. (1985) The thyroid gland with low uptake lesions: evaluation by ultrasound. Radiology 155: 187–191PubMedGoogle Scholar
  26. Solomon B.L., Wartowsky L., Burman D. (1996) Current trends in the management of weil differentiated papillary thyroid carcinoma. J Clin Endocrinol Metab 81: 333–339PubMedCrossRefGoogle Scholar
  27. Uzzan B., Campos J., Cucherat M., Nony P., Boissei J.P., Perret G.Y. (1996) Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis. J Clin Endocrinol Metab 81: 4278–4289PubMedCrossRefGoogle Scholar
  28. Van de Velde C.J.H., Hamming J.F., Goslings B.M. et al.(1988) Report on the consensus development conference on the management of differentiated thyroid cancer in the Netherlands. Eur J Cancer Clin Oneol 24: 287–292CrossRefGoogle Scholar
  29. Wahl R.A., Röher H.D. (1988) Surgery for C-cell-carcinoma of the thyroid. Progr Surg 19: 100–1l2Google Scholar
  30. Wartofsky L. (1993) Does replacement thyroxine therapy cause osteoporosis? Adv Endocrinol Metab 4: 157–175Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2001

Authors and Affiliations

  • J. Feldkamp
  • W. A. Scherbaum

There are no affiliations available

Personalised recommendations